European Life Sciences Report – Site Selection for Life Sciences Companies


Zurich / Singapore, November 2015 – Venture Valuation together with KPMG has released its 2015 Report on “Site Selection for Life Sciences companies in Europe”. The report looks across the European Life Sciences landscape, analysing and comparing 14 European countries. The report looks at the strength of Biotechnology, Medical Technology and Pharma.

This second edition report provides an in depth analysis of seven key life sciences clusters across Europe including Belgium, France, Germany, Ireland, Netherlands, Switzerland and the United Kingdom. These countries were chosen as they represent the main locations to attract direct foreign investment according to KPMG.

The data in the report is based on Venture Valuation’s global Biotechgate database with over 37,000 companies. In total 14 European countries including Austria, Denmark, Finland, Italy, Norway, Spain, Sweden (plus the 7 previously listed countries) are analysed along with Israel and the BayArea in the US. Venture Valuation analysed the number of Life Sciences companies in Biotechnology, Biotechnology – Therapeutics, Medical Technology and Pharma and reviewed their main activities with regards to R&D and manufacturing. A focus is also put on the numbers and activities of global and regional headquarters. The report provides information on the strength of the development pipeline, the therapeutic focus of each country and for each stage of development. Venture valuation also provides a detailed financial analysis on how much money has been raised by companies in the different countries, from the different sectors, looking at private and publicly listed companies.

Germany has the highest number of Biotechnology companies, however, the UK has the higher number of Biotechnology companies developing therapeutics, an indication for innovation. Regarding the pipeline, it is again the UK who leads, followed by Germany, France and Switzerland. In 2015 (Jan-Jul) UK and Swiss private companies raised around 75% of the total money raised by private European companies. Looking at public companies, Dutch and Irish companies raised the most alongside UK companies.

“This new report provides an excellent overview of the European Life Sciences Industry, especially focusing on private, unlisted companies. As this data is difficult to find, the small companies are often not included in such reports. With our unique global database, we can provide very detailed statistical information. Within Biotechgate, we have every single company / asset and financing round listed in our publicly available database, which provides transparency.”
Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland

To download the report please click here »

About us:

Biotechgate (
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 37,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

Venture Valuation AG (
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

For further information, please contact: Patrik Frei, CEO Venture Valuation, Singapore | +41 43 321 8660